New Drugs for Airway Diseases

Singh, Dave

doi:10.1016/b978-0-08-102723-3.00170-0

Cited by 1 publication

(2 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of novel therapies for asthma and COPD requires a precision medicine approach, using both clinical information (clinical phenotype) and biological markers (endotypes) in order to identify subgroups with the greatest potential for therapeutic benefit [ 65 ]. Drugs with novel mechanisms of action are being developed for airway diseases, the most promising new drug classes with identification of responder subgroups are discussed in the following paragraphs.…”

Section: Emerging New Concepts and Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022

Stolz

Matera

Rogliani

et al. 2023

Breathe

Self Cite

View full text Add to dashboard Cite

Pharmacological management of airway obstructive diseases is a fast-evolving field. Several advances in unravelling disease mechanisms as well as intracellular and molecular pathways of drug action have been accomplished. While the clinical translation and implementation ofin vitroresults to the bedside remains challenging, advances in comprehending the mechanisms of respiratory medication are expected to assist clinicians and scientists in identifying meaningful read-outs and designing clinical studies. This European Respiratory Society Research Seminar, held in Naples, Italy, 5–6 May 2022, focused on current and future developments of the drugs used to treat asthma and COPD; on mechanisms of drug action, steroid resistance, comorbidities and drug interactions; on prognostic and therapeutic biomarkers; on developing novel drug targets based on tissue remodelling and regeneration; and on pharmacogenomics and emerging biosimilars. Related European Medicines Agency regulations are also discussed, as well as the seminar's position on the above aspects.

show abstract

Section: Emerging New Concepts and Treatmentsmentioning

confidence: 99%

“…PDE4 inhibition has the potential to exert broad anti-inflammatory effects. Ensifentrine has demonstrated bronchodilation and symptom improvement in COPD clinical trials and has the possibility to be the first novel bronchodilator to be successfully developed for decades [ 65 , 77 ].…”

Section: Emerging New Concepts and Treatmentsmentioning

confidence: 99%